Tag: medicine

FUKUOKA, Japan, Aug. 13, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the pricing of its initial public offering of 1,250,000 Japanese common shares at US$4.00 per share. The Japanese common shares are expected to begin trading on the Nasdaq Capital Market on August 14, 2025, under the ticker symbol "RYOJ". Gross proceeds of the offering before deducting underwriting discounts and other offering expenses are expected to be US$5 million. The offering is expected to close on August 15, 2025, subject to customary closing conditions.

Niagara Falls, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners to a nationally recognized nuclear cardiology group specializing in advanced cardiovascular diagnostics and interventional care.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global AI in Synthetic Biology Market size & share revenue was valued at approximately USD 24.58 Billion in 2024 and is expected to reach USD 30.76 Billion in 2025 and is expected to reach around USD 192.95 Billion by 2034, at a CAGR of 28.63% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Ginkgo Bioworks, Amyris, Thermo Fisher Scientific, Illumina, GenScript, Synthetic Genomics, Novozymes, LanzaTech, Zymergen, Twist Bioscience, Codexis, Cambrian Biopharma, Moderna, Editas Medicine, Vertex Pharmaceuticals, CRISPR Therapeutics, Arbor Biotechnologies, Synthego, Evonik Industries, Cargill, Others and others.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Canine Orthopedics Market size & share revenue was valued at approximately USD 420.2 Million in 2024 and is expected to reach USD 454.6 Million in 2025 and is expected to reach around USD 945.2 Million by 2034, at a CAGR of 8.6% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are B. Braun Melsungen AG, Movora (Vimian Group AB), Integra LifeSciences Corporation, DePuy Synthes (Johnson & Johnson), AmerisourceBergen Corporation, STERIS, Arthrex Inc. (Arthrex Vet Systems), Orthomed (UK) Ltd, Veterinary Instrumentation, BioMedtrix LLC, Fusion Implants Limited, Narang Medical Limited, Zoetis Inc., IMEX Veterinary Inc., Everost Inc and others.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach around USD 252.93 Billion by 2034, at a CAGR of 17.32% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc., Precision Biologics, Danaher Corporation (Cepheid Inc.), GE HealthCare, Celera Diagnostics LLC, Decode Genetics Inc., Exact Sciences Corporation, IBM Corporation, Exagen Inc., Biogen, QIAGEN, Genentech Inc., 23andMe Inc., Asuragen Inc and others.

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.